

RESEARCH ARTICLE

Open Access



Clinical features of patients with hepatic portal venous gas

Manato Fujii^{1*} , Suguru Yamashita¹, Mayuko Tanaka², Jo Tashiro³, Yoshiharu Takenaka¹, Kazuki Yamasaki¹ and Yukiyoshi Masaki¹

Abstract

Background: Hepatic portal venous gas (HPVG) is a rare clinical condition that is caused by a variety of underlying diseases. However, the factors that would permit accurate identification of bowel ischemia, requiring surgery, in patients with HPVG have not been fully investigated.

Methods: Thirty patients that had been diagnosed with HPVG using computed tomography between 2010 and 2019 were allocated to two groups on the basis of clinical and intraoperative findings: those with (Group 1; n = 12 [40%]) and without (Group 2; n = 18 [60%]) bowel ischemia. Eleven patients underwent emergency surgery, and bowel ischemia was identified in eight of these (73%). Four patients in Group 1 were diagnosed with bowel ischemia, but treated palliatively because of their general condition. We compared the characteristics and outcomes of Groups 1 and 2 and identified possible prognostic factors for bowel ischemia.

Results: At admission, patients in Group 1 more commonly showed the peritoneal irritation sign, had lower base excess, higher lactate, and higher C-reactive protein, and more frequently had comorbid intestinal pneumatosis. Of the eight bowel ischemia surgery patients, four (50%) died, mainly because of anastomotic leak following bowel resection and primary anastomosis (3/4, 75%). All except one patient in Group 2, who presented with aspiration pneumonia, responded better to treatment.

Conclusions: Earlier identification and grading of bowel ischemia according to the findings at admission should benefit patients with HPVG by reducing the incidence of unnecessary surgery and increasing the use of safer procedures, such as prophylactic stoma placement.

Keywords: Hepatic portal venous gas, Bowel ischemia, Predictive factors

Background

Hepatic portal venous gas (HPVG), which was first recognized in neonates by Wolf et al. [1] and in adults by Susman et al. [2], has been reported to be associated with three major inciting factors: bowel mucosal damage, bowel distention, and sepsis [3]. On the basis of early studies that used plain abdominal radiography, HPVG was regarded as a life-threatening pathology that

principally reflected bowel ischemia [3, 4]. However, the advent of more advanced imaging techniques, such as multi-detector computed tomography (CT), which have excellent spatial and contrast resolution, have increased the sensitivity of HPVG detection [5, 6], and consequently the number of reports of HPVG patients without bowel ischemia. Specifically, HPVG that is not related to abdominal pathology [7, 8] and iatrogenic HPVG [9–14] are increasingly recognized in this era of multi-disciplinary examinations and interventions. Then, the more recent literature [15, 16] has reported a reduction in the mortality rate of patients with HPVG to ~ 40%, due to the study of larger number of patients that did not have

*Correspondence: manatonama@gmail.com

¹ Department of Surgery, Ome Municipal General Hospital, 4-16-5, Higashi Ome, Ome-shi, Tokyo 198-0042, Japan
Full list of author information is available at the end of the article



© The Author(s) 2020. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

bowel ischemia, which compares with the oft-cited mortality rates described in earlier reports of ~75% [3].

HPVG is not a specific disease, but instead can be attributable to a variety of contrasting underlying pathologies. Since bowel ischemia has been widely recognized as the leading lethal etiological factor among many background pathologies of HPVG [17], it is clinically essential to identify the presence of bowel ischemia and to grade its severity in HPVG patients. Although there is a growing body of literature regarding HPVG patients who did not have life-threatening pathology, in the context of the advances in imaging sensitivity, HPVG remains a rare condition and the majority of the literature comprises case series. Indeed, recent researchers have calculated the overall incidence of HPVG to be only 0.06%–0.12%, on the basis of retrospective radiologic reviews conducted in academic medical settings [18, 19]. As such, the factors involved in the accurate prediction of bowel ischemia in patients with HPVG have not been able to be fully investigated to date.

The aims of the current study were two-fold: (1) to report the characteristics and outcomes of a recent set of consecutive HPVG patients at a tertiary hospital comparing those with data in the published article, and (2) to determine the predictors for the identification of bowel ischemia in such a cohort.

Methods

Study design and population

This retrospective study was performed at a single tertiary hospital in Tokyo, Japan. The study protocol conformed to the ethical guidelines of the Ome Municipal General Hospital, as reflected in a priori approval by the institutional review board (Referee number, 46). Because of the retrospective nature of the study, informed consent was not required. All procedures were conducted in accordance with the principles of the Helsinki Declaration of 1975, as revised in 1983.


Between 2010 and 2019, we enrolled 30 consecutive adult patients with HPVG diagnosed using multi-detector CT (Aquilion 64, Canon, Japan) by the experienced attending diagnostic radiologist. Twenty-two patients underwent contrast-enhanced CT and eight underwent non-enhanced CT. The radiologic definition of HPVG was a tubular area of low attenuation in the liver periphery, as described previously [20]. The following were transcribed from the electronic medical record: age, sex, body mass index, principal complaints, history of abdominal surgery, comorbidities, regular medication (for example, alpha-glucosidase inhibitors [9]), and the laboratory findings at admission (pH, base excess [BE], serum lactate concentration, white blood cell count, neutrophil-to-lymphocyte ratio [NLR] [21], the lactate

dehydrogenase and creatine kinase activities, and the C-reactive protein [CRP] concentration). The following CT findings at diagnosis of HPVG were also reviewed: intestinal pneumatosis (IP), portomesenteric venous gas, bowel wall attenuation in the post-contrast phase, ascites, free air, type of IP [16], and the distribution of HPVG [19, 20].

While clinical diagnosis of bowel ischemia was mainly obtained by enhanced CT on admission, given its well-established high sensitivity and specificity [22], comprehensive assessment based on physical, hematological, and radiological findings remained essential especially in the patients who could receive only non-enhanced CT. Emergency surgery was performed if there was a clinical suspicion of bowel ischemia. According to the intraoperative findings, an appropriate procedure (for example, exploratory laparotomy alone or bowel resection with pathologic evaluation of specimen) was performed. In terms of intraoperative bowel findings, surgeons focused on the presence or absence of return of color, arterial pulsations, and visible peristalsis. Previous literature demonstrated the favorable consistency between those gross appearances obtained by experienced surgeon and pathological results regarding the diagnosis of bowel ischemia [23]. On the basis of clinical, intraoperative, and pathologic findings, the identity of the underlying disease in the HPVG cohort was determined, then the patients were allocated to two groups: those with (Group 1; n = 12 [40%]) and those without (Group 2; n = 18 [60%]) bowel ischemia (Fig. 1). Emergency surgery was performed in 11 patients (37%) and bowel ischemia was identified in eight of these (73%). Four patients in Group 1 were clinically diagnosed with bowel ischemia but were treated palliatively because of their poor general condition (Fig. 1). We then compared the characteristics of Groups 1 and 2 to determine the potential prognostic factors for bowel ischemia. The therapeutic course after admission, including the perioperative findings, was reviewed on the patients' medical charts.

Statistical analyses

Continuous data were compared using the Wilcoxon rank-sum test and categorical data were compared using the χ^2 test. The performance of laboratory values in the prediction of bowel ischemia was assessed using receiver operating characteristic (ROC) analysis and optimal cut-off values were determined. The accuracy with which these parameters discriminated patients with and without bowel ischemia was assessed by calculating the areas under the curves (AUCs). $P < 0.05$ was considered to represent statistical significance in all the analyses. Statistical analyses were performed using JMP software (version 15; SAS Institute, Cary, NC, USA).



Results

Categorization of patient characteristics according to presence of bowel ischemia

The clinical and radiologic data for patients with (Group 1; $n=12$ [40%]) and without bowel ischemia (Group 2; $n=18$ [60%]) are summarized in Table 1. Compared with patients in Group 2, those in Group 1 were more likely to present with the peritoneal irritation sign, to have lower BE and higher lactate, NLR, and CRP on admission. With regard to the CT findings, the incidence of a combination of IP and HPVG in Group 1 was significantly higher than that in Group 2, but there were no significant differences between Groups 1 and 2 with regard to the prevalences of ascites or free air, or the distribution of HPVG. Because none of the patients had HPVG that was limited to the right side of the liver, we confirmed that the left side of the liver is the predominant site for HPVG to develop, as previously described [19, 20]. In Group 1 patients, the most common specific cause of bowel ischemia was non-occlusive mesenteric ischemia (8/12, 75%), but the four patients that only received palliative care in Group 1 were not autopsied.

Laboratory measurements (BE, lactate, and CRP) that were made on admission and were candidates for use in the prediction of bowel ischemia were assessed using ROC analysis (Additional file 1: Fig. S1A). This analysis was not applied to NLR because of substantial number of missing data (15/30). ROC analyses revealed that BE (AUC 0.831, $p=0.005$), lactate (AUC 0.850, $p=0.003$), and CRP (AUC 0.819, $p=0.007$) were significantly associated with bowel ischemia and the optimal cut-off values for the prediction of bowel ischemia were -5.5 mmol/L , 3.5 mmol/L , and 4.4 mg/dL , respectively (Additional file 1: Fig. S1B, C, D).

Predictors of bowel ischemia in patients

without the peritoneal irritation sign ($n=23$)

On the basis of the data in Table 1, emergency surgery is clearly justified in HPVG patients with the peritoneal irritation sign, because of its 100% (7/7) positive predictive value for bowel ischemia. However, it may be more important to identify the presence of bowel ischemia in HPVG patients without the peritoneal irritation sign, because its negative predictive value for bowel ischemia was unsatisfactory (18/23, 78%) (Table 1). Therefore, we analyzed the incidence of bowel ischemia in patients without the peritoneal irritation sign ($n=23$), focusing on IP on CT finding, BE, lactate, and CRP (Fig. 2). To dichotomize BE, lactate, and CRP, accurate thresholds were selected according to the results of the ROC analyses (Additional file 1: Figure S1). Lower BE and higher lactate on admission remained significant predictors of bowel ischemia, even in HPVG patients without the peritoneal irritation sign (Fig. 2).

Therapeutic course

Table 2 summarizes the perioperative findings in Group 1 patients, particularly those who underwent emergency surgery ($n=8$). Although emergency surgery was performed after a median of only 7.1 h post-arrival, the postoperative outcomes were still poor (50% mortality [4/8]). Of note, three of the four patients who underwent bowel resection and primary anastomosis experienced anastomotic leak, which lead to mortality in all three cases. The cause of death of the remaining patient, who had undergone successful adhesiolysis, was severe sepsis due to preoperative aspiration pneumonia. Four patients who showed clinical evidence of bowel ischemia but underwent palliation alone died a median of 1 day following admission (range, 1–6 days). In general, patients

Table 1 Patient characteristics

	Total n=30	Ischemia (Group 1) n=12	Non-ischemia (Group 2) n=18	P ^d
Age (years)	72 (53–92)	74 (55–90)	72 (53–92)	0.816 ^e
Male, n (%)	19 (63)	6 (50)	13 (72)	0.216
Body mass index, kg/m ²	20.9 (15.2–29.0)	22.0 (17.1–28.2)	20.6 (15.2–29.0)	0.421 ^e
Principal complaints ^a				
Abdominal pain, n (%)	23 (77)	9 (75)	14 (78)	0.860
Peritoneal irritation sign, n (%)	7 (23)	7 (58)	0 (0)	< 0.001
Nausea, n (%)	10 (33)	2 (17)	8 (44)	0.114
Impaired consciousness, n (%)	4 (13)	2 (17)	2 (11)	0.661
Gastrointestinal bleeding, n (%)	4 (13)	0 (0)	4 (22)	0.079
Abdominal fullness, n (%)	3 (10)	0 (0)	3 (17)	0.136
Fever, n (%)	2 (6.7)	1 (8.3)	1 (5.6)	0.765
History of abdominal surgery, n (%)	9 (30)	3 (25)	6 (33)	0.626
Hypertension, n (%)	18 (60)	6 (50)	12 (67)	0.361
Diabetes mellitus, n (%)	12 (40)	4 (33)	8 (44)	0.543
Use of alpha-glucosidase inhibitor, n (%)	6 (20)	1 (8.3)	5 (28)	0.192
Use of psychotropic agent, n (%)	8 (27)	3 (25)	5 (28)	0.866
Use of anticoagulant agent, n (%)	10 (33)	2 (17)	8 (44)	0.114
Use of steroid, n (%)	3 (10)	2 (17)	1 (5.6)	0.320
Laboratory findings				
pH ^b	7.42 (6.98–7.61)	7.38 (6.98–7.57)	7.42 (7.36–7.61)	0.114 ^e
Base excess, mmol/L ^b	0.9 (−27.6–6.6)	-4.4 (-27.6–2.5)	2.3 (-5.2–6.6)	0.005 ^e
Lactate, mmol/L ^b	2.1 (0.8–13.8)	5.2 (1.2–13.8)	1.8 (0.8–5.1)	0.003 ^e
White blood cell, /µL	9990 (2230–45,090)	12,720 (2,230–45,090)	9330 (4930–26,100)	0.290 ^e
Neutrophil lymphocyte ratio ^c	9.3 (1.3–29)	21 (7.7–29)	6.6 (1.3–18)	0.013 ^e
Lactate dehydrogenase, IU/L	207 (137–619)	207 (147–619)	207 (137–586)	0.757 ^e
Creatine kinase, IU/L	68 (20–595)	71 (20–595)	60 (26–135)	0.338 ^e
C-reactive protein, mg/dL	4.0 (0–48)	9.7 (1.2–48)	2.8 (0–20)	0.016 ^e
Computed tomography findings				
Intestinal pneumatosis, n (%)	15 (50)	9 (75)	6 (33)	0.025
Band like pneumatosis [16], n (%)	11 (37)	8 (67)	3 (17)	0.005
Bubble like pneumatosis [16], n (%)	4 (13)	1 (8.3)	3 (17)	0.511
Ascites, n (%)	14 (47)	5 (42)	9 (50)	0.654
Free air, n (%)	2 (6.7)	2 (17)	0 (0)	0.073
Distribution of HPVG [19]				
Bilobar, n (%)	18 (60)	6 (50)	12 (67)	0.361
Limited to left liver, n (%)	12 (40)	6 (50)	6 (33)	0.361
Underlying disease as cause of HPVG				
Bowel ischemia	12 (40)	12 (100)	0 (0)	< 0.001
Enteritis	10 (33)	0 (0)	10 (56)	0.002
Bowel distention	6 (20)	0 (0)	6 (33)	0.025
Pneumothorax	1 (3.3)	0 (0)	1 (5.6)	0.406
Unknown	1 (3.3)	0 (0)	1 (5.6)	0.406

Data are presented as median (range) unless otherwise indicated

Italic values indicate items represented statistical significance

HPVG hepatic portal venous gas

^a Overlap of principal complaints was allowed^b Data of 4 patients are missing^c Data of 15 patients are missing^d χ^2 test unless otherwise indicated^e Wilcoxon rank-sum test




Fig. 2 Incidence of bowel ischemia in patients without the peritoneal irritation sign (n = 23). The incidences of bowel ischemia in patients without the peritoneal irritation sign were compared using the χ^2 test. IP, intestinal pneumatosis; BE, base excess; CRP, C-reactive protein

Table 2 Operative findings in patients undergoing surgery for ischemia (n = 8)

Interval from arrival to surgery, median (range), h	7.1 (3.4–34)
Surgical procedure	
Small bowel resection, n (%) ^a	4 (50)
Colectomy, n (%) ^b	2 (25)
Primary repair for perforation, n (%)	1 (13)
Adhesiolysis, n (%)	1 (13)
Operative time, median (range), min	148 (45–198)
Estimated blood loss, median (range), cc	85 (10–330)
Mortality, n (%)	4 (50)
Postoperative survival in mortality cases, median (range), days	8.5 (2–59)

^a Three of 4 patients underwent primary anastomosis and the other had prophylactic stoma

^b One patient underwent primary anastomosis and the other had prophylactic stoma

in Group 2 showed satisfactory therapeutic courses when undergoing conservative therapy alone, depending on the identity of the underlying disease, with a median of

16 days of hospitalization (range 3–45), except for one who died of aspiration pneumonia secondary to enteritis on the 14th day following admission. Images of a representative case of HPVG are shown in Fig. 3. The mortality rate for the full cohort that had presented with HPVG during the past decade was 30% (9/30).

Discussion

This study found that while the majority of HPVG patients (18/30, 60%) did not have bowel ischemia, it was the most common specific underlying disease in adults with HPVG (12/30, 40%), which is consistent with earlier reports [3, 18]. Our results suggested that bowel ischemia in HPVG patients should still be regarded as an ominous radiologic sign, in contrast to the favorable outcomes in HPVG patients without bowel ischemia. Indeed, the mortality of HPVG patients with bowel ischemia who had undergone surgery was 50% (4/8). In particular, three out of four patients who underwent bowel resection and primary anastomosis suffered from anastomotic leak, which directly lead to mortality, suggesting that the use




Fig. 3 Representative case with hepatic portal venous gas. A 70–80-year-old thin patient, who had experienced multiple system atrophy, associated with poor Eastern Cooperative Oncology Group performance status, presented to the emergency department complaining of abdominal distension and nausea. An abdominal CT performed on admission revealed diffuse distension of the small intestine, a suspicion of pneumatoxisis in the terminal ileum (**a** arrow), and portal (**b, c** arrow) and mesenteric venous gas (C, arrowhead). Given the absence of solid evidence of bowel obstruction and ischemia (lack of the peritoneal irritation sign, a base excess of -1.6 mmol/L , and a lactate concentration of 2.7 mmol/L), it was decided to treat her with fasting and antibiotics. Following radiological confirmation of significant improvement in the ileal pneumatoxisis and portal and mesenteric venous gas on the third day following admission, she was discharged in a satisfactory condition after 4 weeks of conservative therapy

of an earlier second-look laparotomy and/or a prophylactic stoma should be considered in such patients. Modern surgical techniques, such as fluorescent angiography for the verification of intraoperative vascular perfusion, might have a positive effect on the prognosis of those who are predisposed to postoperative anastomotic leak [24].

We also found that the peritoneal irritation sign, several laboratory findings on admission (BE, lactate, NLR, and CRP), and IP on CT represented potential prognostic factors for bowel ischemia in the full cohort with HPVG, although this finding was based on univariable analyses, because of the relatively small sample size. In particular, dichotomized BE and lactate remained significant predictors of bowel ischemia, even in HPVG patients without the peritoneal irritation sign ($n=23$). Patients who present with obscure symptoms, because

of their highly advanced age or impaired consciousness, for example, might benefit from measurement of these variables at diagnosis. These variables, other than NLR, have been already reported to be candidate predictors of bowel ischemia in patients with HPVG [16, 25–30]. However, no previous reports have described an association between high NLR and bowel ischemia in HPVG patients, although some researchers have suggested that NLR might be useful for the identification of, and assessment of the severity of, acute mesenteric ischemia [31]. Further research on nomogram development integrating such potentially predictable factors on bowel ischemia may be required for swifter determination of operative indication in HPVG patients, given the current dismal mortality rate in patients with bowel ischemia undergoing emergency surgery.

In the present cohort, three of eleven patients (27%) undergoing emergency surgery had an exploratory laparotomy alone, due to intraoperative recognition of the absence of bowel ischemia, and were subsequently managed without bowel resection. Such over-diagnosis might be justified in the context of the highly unfavorable outcomes in HPVG patients who do have bowel ischemia. However, further refinement of the methods used for the identification of underlying disease in HPVG patients should reduce the need for unnecessary surgery. This might also contribute to more rapid decision-making regarding the necessity for emergency surgery, which could reduce mortality, although in the present study there was a median of only 7.1 h (range 3.4–34) between arrival and surgery. In addition, the identification, not only of the presence of bowel ischemia in HPVG patients, but also of its severity, would be clinically relevant for the selection of the safest procedure (for example, the creation of a prophylactic stoma or not) during emergency surgery. For instance, previous studies have demonstrated that the type of IP (band-like or bubble-like) is significantly associated with the severity of bowel ischemia [16, 32], but this relationship could not be validated in the present, relatively small cohort.

The present study had a few limitations, including its retrospective nature and the small number of patients with HPVG studied, which meant that multivariable analysis of the potential predictors of bowel ischemia could not be performed. Second, there was a significant proportion of patients (4/30, 13%) who presented with impaired consciousness as their principal complaint, and whose physical findings, including the peritoneal irritation sign, were difficult to establish. Third, eight of the 30 patients (27%) were diagnosed using non-enhanced CT, because of renal functional impairment or drug allergy. Moreover, in Group 1 ($n=12$), diagnosis of bowel ischemia was made by only clinical findings in 4 patients and the remaining 8 patients obtained intraoperative confirmation of bowel ischemia. But such diagnostic heterogeneity is reflective of general clinical practice and is consistent with previous findings [16].

Conclusions

While HPVG can be the result of a wide spectrum of underlying diseases, including non-ischemic conditions, critical abdominal pathologies should be identified promptly and accurately, given the high mortality in patients with bowel ischemia even undergoing emergency surgery. Further advancements in diagnostic capabilities, with the use of parameters that are potentially predictive of bowel ischemia, and in perioperative management, including the selection of safer surgical procedures, might improve the outcomes in HPVG patients.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12893-020-00973-8>.

Additional file 1: Figure S1. Receiver operating characteristic curves for the use of laboratory parameters measured at admission for the prediction of bowel ischemia. The accuracy for the discrimination of patients with and without bowel ischemia was assessed by calculating the areas under the curves for base excess, lactate, and C-reactive protein on admission (A). Appropriate thresholds for the prediction of bowel ischemia were determined to be – 5.5 mmol/L for base excess (B), 3.5 mmol/L for lactate (C), and 4.4 mg/dL for C-reactive protein (D). AUC, area under the curve; CI, confidence interval; SE, standard error. The P values indicate the usefulness of the parameter as a predictor (null hypothesis, AUC = 0.500).

Abbreviations

HPVG: Hepatic portal venous gas; CT: Computed tomography; BE: Base excess; NLR: Neutrophil-to-lymphocyte ratio; CRP: C-reactive protein; IP: Intestinal pneumatosis; ROC: Receiver operating characteristic; AUCs: Areas under the curves.

Acknowledgements

The authors would like to thank Mark Cleasby, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

Authors' contributions

MF designed the study, performed the research, acquired the data, and drafted the manuscript. SY revised the manuscript. MF, SY, MT, JT, YT, KY and YM were responsible for the integrity of the data and accuracy of the data analysis. All authors read and approved the final manuscript.

Funding

No grant support or other funding was received.

Availability of data and materials

All data and materials concerning this research article are available for sharing if needed.

Ethics approval and consent to participate

The authors report no conflicts of interest relevant to this article. This study was conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethical Committee of Ome Municipal General Hospital (approval number: 46). Because of the retrospective nature of the study, informed consent was not required.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Surgery, Ome Municipal General Hospital, 4-16-5, Higashi Ome, Ome-shi, Tokyo 198-0042, Japan. ² Department of Radiology, Ome Municipal General Hospital, 4-16-5, Higashi Ome, Ome-shi, Tokyo 198-0042, Japan. ³ Department of Surgery, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan.

Received: 18 July 2020 Accepted: 18 November 2020

Published online: 27 November 2020

References

- Wolf JN, Evans WA. Gas in the portal veins of the liver in infants: a roentgenographic demonstration with postmortem anatomical correlation. Am J Roentgen Radium Ther Nucl Med. 1955;74:486–8.

2. Susman N, Senturia HR. Gas embolization of the portal venous system. Am J Roentgenol Radium Ther Nucl Med. 1960;83:847–50.
3. Lieberman PR, Patten MT, Manny J, et al. Hepatic-portal venous gas in adults: etiology, pathophysiology and clinical significance. Ann Surg. 1978;187:281–7.
4. Bevan K, Griffiths MV, Morgan MH. Superior laryngeal nerve injury: an overlooked entity in the surgery of the head and neck. Br J Surg. 1988;75:817.
5. Mourad FH, Leong RW. Gas in the hepatic portal venous system associated with ischemic colitis. Am J Gastroenterol. 2018;113:1280.
6. Shah PA, Cunningham SC, Morgan TA, et al. Hepatic gas: widening spectrum of causes detected at CT and US in the interventional era. Radiographics. 2011;31:1403–13.
7. Rovito V. Hepatic-portal vein gas associated with bronchopneumonia. Am J Gastroenterol. 1982;77:243–4.
8. Chen KW, Shin JS, Chi CH, et al. Seizure: a rare and transient cause of portal venous gas. Am J Gastroenterol. 1997;92:351–2.
9. Makiyama H, Kataoka R, Tauchi M, et al. Do alpha-glucosidase inhibitors have the potential to induce portal venous gas? -Two clinical case reports. Intern Med. 2014;53:691–4.
10. Quirke TE. Hepatic-portal venous gas associated with ileus. Am Surg. 1995;61:1084–6.
11. Alqahtani S, Coffin CS, Burak K, et al. Hepatic portal venous gas: a report of two cases and a review of the epidemiology, pathogenesis, diagnosis and approach to management. Can J Gastroenterol. 2007;21:309–13.
12. Ortega J, Hayes JM, Antonia S. Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol. 2009;65:187–90.
13. Oei T, vanSonnenberg E, Shankar S, et al. Radiofrequency ablation of liver tumors: a new cause of benign portal venous gas. Radiology. 2005;237:709–17.
14. Chezmar JL, Nelson RC, Bernardino ME. Portal venous gas after hepatic transplantation: sonographic detection and clinical significance. AJR Am J Roentgenol. 1989;153:1203–5.
15. Kinoshita H, Shinozaki M, Tanimura H, et al. Clinical features and management of hepatic portal venous gas: four case reports and cumulative review of the literature. Arch Surg. 2001;136:1410–4.
16. Wiesner W, Mortelé KJ, Glickman JN, et al. Pneumatosis intestinalis and portomesenteric venous gas in intestinal ischemia: correlation of CT findings with severity of ischemia and clinical outcome. AJR Am J Roentgenol. 2001;177:1319–23.
17. Chen H, Wu Q, Fang H, et al. Intestinal necrosis cannot be neglected in a patient with hepatic portal vein gas combined with appendicitis: a rare case report and literature review. BMC Surg. 2019;19:17.
18. Faberman RS, Mayo-Smith WW. Outcome of 17 patients with portal venous gas detected by CT. AJR Am J Roentgenol. 1997;169:1535–8.
19. Schindera ST, Triller J, Vock P, et al. Detection of hepatic portal venous gas: its clinical impact and outcome. Emerg Radiol. 2006;12:164–70.
20. Sebastià C, Quiroga S, Espin E, et al. Portomesenteric vein gas: pathologic mechanisms, CT findings, and prognosis. Radiographics. 2000;20:1213–26.
21. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55–60.
22. Menke J. Diagnostic accuracy of multidetector CT in acute mesenteric ischemia: systematic review and meta-analysis. Radiology. 2010;256:93–101.
23. Bulkley GB, Zuidema GD, Hamilton SR, et al. Intraoperative determination of small intestinal viability following ischemic injury: a prospective, controlled trial of two adjuvant methods (Doppler and fluorescein) compared with standard clinical judgment. Ann Surg. 1981;193:628–37.
24. Liot E, Assalino M, Buchs NC, et al. Does near-infrared (NIR) fluorescence angiography modify operative strategy during emergency procedures? Surg Endosc. 2018;32:4351–6.
25. Higashizono K, Yano H, Miyake O, et al. Postoperative pneumatosis intestinalis (PI) and portal venous gas (PVG) may indicate bowel necrosis: a 52-case study. BMC Surg. 2016;16:42.
26. Buras R, Guzzetta P, Avery G, et al. Acidosis and hepatic portal venous gas: indications for surgery in necrotizing enterocolitis. Pediatrics. 1986;78:273–327.
27. Koami H, Isa T, Ishimine T, et al. Risk factors for bowel necrosis in patients with hepatic portal venous gas. Surg Today. 2015;45:156–61.
28. Nelson AL, Millington TM, Sahani D, et al. Hepatic portal venous gas: the ABCs of management. Arch Surg. 2009;144:575–81.
29. Hou SK, Chern CH, How CK, et al. Hepatic portal venous gas: clinical significance of computed tomography findings. Am J Emerg Med. 2004;22:214–8.
30. Peloponissios N, Halkic N, Pugnale M, et al. Hepatic portal gas in adults: review of the literature and presentation of a consecutive series of 11 cases. Arch Surg. 2003;138:1367–70.
31. Tanrikulu Y, Şen Tanrikulu C, Sabuncuoğlu MZ, et al. Diagnostic utility of the neutrophil-lymphocyte ratio in patients with acute mesenteric ischemia: A retrospective cohort study. Ulus Travma Acil Cerrahi Derg. 2016;22:344–9.
32. Pear BL. Pneumatosis intestinalis: a review. Radiology. 1998;207:13–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

